Design Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| DSGN | SLDB | MGTX | STOK | RGNX | SRPT | |
|---|---|---|---|---|---|---|
| Market cap | 682.77M | 719.48M | 996.93M | 1.56B | 512.92M | 1.84B |
| P/E (TTM) | — | — | 11.9 | — | — | — |
| Forward P/E | -6.7 | -3.9 | -6.8 | -6.8 | -2.6 | 7.3 |
| Price/book | 3.4 | 1.9 | 4.5 | 4.4 | 5.9 | 1.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +79.51% | +14.31% | +36.53% | −18.46% | −28.84% | −18.72% |
| Today | −6.35% | −2.33% | −2.90% | −2.38% | −3.72% | −2.30% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All DSGN news ›Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027
Seeking Alpha - Design Therapeutics is initiated with a "Hold" rating as its lead candidate, DT-216P2 targets the root cause of Friedreich Ataxia [FA]. - The company's 4-week phase 1/2 RESTORE-FA data showed strong biomarker and clinical…
Design Therapeutics, Inc. (NASDAQ:DSGN) Stock Has Average Target Price of $16.50 According to Brokerages
Posted by Mitch Edgeman on Oct 3rd, 2026 Several equities research analysts have recently issued reports on DSGN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Design Therapeutics in a research report on Friday, July…
Design Therapeutics a new overweight at Wells Fargo on Friedreich ataxia program
Wells Fargo rates Design Therapeutics overweight, citing DT-216P2’s RESTORE-FA data and best-in-disease potential vs Skyclarys. Read more here.
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
prnewswire.com2
-
theaiinsider.tech2
-
macaubusiness.com1
-
manilatimes.net1
-
pulse2.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.